SGRY VS BBIO Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilitySentiment
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilitySentiment

Performance

SGRY
10/100

SGRY returned 4.97% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

BBIO
100/100

BBIO returned 125.25% in the last 12 months. Based on SPY's performance of -21.29%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

SGRY
61/100

9 analysts offer 12-month price targets for SGRY. Together, they have an average target of 64, the most optimistic target put SGRY at 64 within 12-months and the most pessimistic has SGRY at 64.

BBIO

"Analyst Price Targets" not found for BBIO

Technicals

SGRY
64/100

SGRY receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

BBIO
21/100

BBIO receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

SGRY
10/100

SGRY has missed earnings 11 times in the last 20 quarters.

BBIO
10/100

BBIO has missed earnings 12 times in the last 20 quarters.

Profit

SGRY
61/100

Out of the last 20 quarters, SGRY has had 14 profitable quarters and has increased their profits year over year on 7 of them.

BBIO
10/100

Out of the last 20 quarters, BBIO has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

SGRY
47/100

SGRY has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

BBIO
53/100

BBIO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Sentiment

SGRY

"Sentiment" not found for SGRY

BBIO
69/100

BBIO had a bullish sentiment score of 69.45% across Twitter and StockTwits over the last 12 months. It had an average of 25.43 posts, 8.91 comments, and 33.77 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Surgery Partners, Inc. Common Stock Summary

Nasdaq / SGRY
Healthcare
Medical - Care Facilities
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

BridgeBio Pharma, Inc. Common Stock Summary

Nasdaq / BBIO
Healthcare
Biotechnology
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.